USAEUROPEViVE
ABOUTSPONSORSHIPFOUNDATION
Logo Hlth
Logo Hlth
07 Dec 2022 | 03:45 PM GMT

DTx-Drug Combination Therapy: What Should the Trial Look Like?

Anchored by:

Myles Furnace
Chief Commercial Officer
EOLAS MEDICAL

Participants:

Myles Furnace Chief Commercial OfficerEolas Medical
Myles Furnace
Chief Commercial OfficerEolas Medical
Anand Trivedi ZSConsultant
Anand Trivedi
ZSConsultant
Fulvio Michelis Digital Strategy DirectorMerck KGaA
Fulvio Michelis
Digital Strategy DirectorMerck KGaA
Jeff Wandzura CEOKEEP Labs
Jeff Wandzura
CEOKEEP Labs
Jock Thompson CEOHyduro, Inc.
Jock Thompson
CEOHyduro, Inc.
Matt Norton VP of Marketing & Commercial DevelopmentS3 Connected Health
Matt Norton
VP of Marketing & Commercial DevelopmentS3 Connected Health
Nicolas Bégin Chief Operations OfficerCureety
Nicolas Bégin
Chief Operations OfficerCureety
Simon Bock Market Access ManagerTiefenbacher Pharmaceuticals
Simon Bock
Market Access ManagerTiefenbacher Pharmaceuticals

About this Meeting

Small, intimate and participant-led discussions tackling digital health challenges. Spaces are limited to 8 - 12 people, allowing you to focus on quality in-depth conversations. 

 DTx-Drug combinations can improve the treatment value, thus leading to better patient outcomes. Many partnerships between pharma and DTx companies happen when the drug is already in the market, hence the specific combination is rarely tested in clinical trials. However, we are seeing more interest in starting these partnerships earlier to co-develop and test the drug and DTx together. Join this session to know more about: 

  • What should the trial look like when combining a drug and DTx solution? What are the needs and requirements to perform a successful trial? 
  • Challenges in selecting the right control arm and how to overcome those. 
  • How can digital endpoints be used in clinical trials for DTx-Drug combination? How to use digital endpoints that will be accepted by the regulators? 
  • How should they wisely pick the combination label claims to help maximize future promotions and adoption strategies? How can they select the right endpoints that support the desired label claims? 
  • Pharma may be risk-averse when it comes to running trials with a DTx solution, as it may show more drug’s weaknesses and can come across as ‘the drug alone is not enough’. How can we de-risk these clinical trials for pharma?
We would like to remind you that our meetings are small and intimate sessions with a limited number of seats available, therefore we rely on your attendance and participation to ensure a high quality and valuable meeting for all. If you are confirmed for this meeting we ask if you can please ensure your attendance on the day.